Member Info for elrico

https://twitter.com/LEMMINGINVESTOR/status/1286362970570870784

I'm sure he is thoroughly lovely fellow when he isn't ****ed and tweeting gay porn on Twitter or allowing his feud with TW - over TRAKM8 and SOS plus others.

https://twitter.com/LEMMINGINVESTOR/status/1286020528348770304

NOT CORRECT SERIOUS ERRORS AND OR ALLOWING A RIGHT TO REPLY WHEN OTHER CORPS HAVE CLEARLY DEMONSTRATES THERE IS AN AGANEDA. Not a good light for Stockopedia, IMHO.

https://twitter.com/LEMMINGINVESTOR/status/1285620365331517444

https://lemminginvestors.blogspot.com/2020/07/optibiotix-health-trading-and.html

Have you heard ‘Stuart Ashman - CEO of SkinBiotherapeutics Plc’ by lemming investors on #SoundCloud? #np https://soundcloud.com/user-957798193-127487236/stuart-ashman-ceo-of-skinbiotherapeutics-plc
#SBTX
https://twitter.com/LEMMINGINVESTOR/status/1281192961510866955

Hailo, Because OPTI cannot predict or make assumptions how sales will build from new product/partner launches. SOH has said many times he want reliable sales data and you cannot get this from the first 12 months of a new partnership.

The ultra cautious stance is a concern for many investors, but SOH appears to want the hard numbers do the talking at this very early stage of commercial traction. Most of the recurring revenues are from early small partner adopters. We are now seeing larger partners adopting and launching new products and these are coming on stream earlier than the first mover partners because there is growing confidence in the science now that just wasn't there 18 months ago.

Almost a year ago I asked if SOH would be more comfortable offering forecasts to the market? He said yes, but here we are he is still reluctant and for good reason. There have been a number of example of products being launched that he was not kept aware of. While this is good news, how many have launched late? This creates a problem with accuracy investors need to make a decision.

Woolworth, Do you call every blogger a messenger? I ask questions, some are my own, some are on behalf of investors.

https://lemminginvestors.blogspot.com/2020/07/optibiotix-health-interview-with.html

OPTI sleuth, AJS has found a number of interesting links promoting the AlfaSigma LP-LDL trial/product which I imagine will offer further validation and build sales momentum.

http://www.dailyhealthindustry.it/alfasigma-arriva-il-primo-integratore-con-ldpl-ID17582.html

https://www.imalatiinvisibili.it/2020/07/03/colesterolo-alto-in-arrivo-nuova-classe-di-integratori-che-contengono-lpldl/

https://informatori.it/flash-news/ricerca-e-sviluppo/alfasigma-arriva-il-primo-integratore-con-ldpl/

https://lemminginvestors.blogspot.com/2020/01/optibiotix-health-alfasigma-launch.html

I will be recording a podcast with SOH in about an hour. I'll post later this evening.
More podcast here https://soundcloud.com/you/tracks

https://lemminginvestors.blogspot.com/2020/07/optibiotix-health-actial-farmaceutica.html

BTW. SOH has stated a number of times he expect OPTI to be profitable at FY 2020. If you believe there will be a repeat of one-off as there were last year I understand scepticism. However, if you are of this mindset why be invested, sell and move on. Sales as of H1 are at the level of FY 2019 and we should all be aware OPTI royalty payments are H2 heavy, and represent the lions share of overall sales.

A number of deals are or are about to generate recurring revenues which should further boost H2 and H1 2021. More and more deals are generating revenues and the latter deals are generating revenues within weeks, no longer 9-12 months because the IP is gaining trust from corporates due to earlier deals. This has taken time, the rewards are starting to drop to the bottom-line.

The 2nd part of the podcast
https://lemminginvestors.blogspot.com/2020/06/optibiotix-health-stephen-ohara-podcast.html

https://lemminginvestors.blogspot.com/2020/06/optibiotix-health-stephen-ohara-podcast.html

IBS angle
https://twitter.com/LEMMINGINVESTOR/status/1268856026754924546

Part1 & 2

https://lemminginvestors.blogspot.com/2020/06/skinbiotherapeutics-stuart-ashman.html

https://soundcloud.com/user-957798193-127487236/stuart-asham-04062020-m4a

https://soundcloud.com/user-957798193-127487236/powerhouse-skinbiotherapeutics-optibiotix

https://lemminginvestors.blogspot.com/2020/02/powerhouse-energy-excitable-investors.html

There were no podcasts or interviews ahead of the previous 3 attempts to breach 72p. IMHO we would have pushed through 72p had it not been for a bank holiday weekend. Sometimes the TA nonsense can be nothing more than a self-fulfilling prophecy. There are a lot of LTHs also trading OPTI in the hope to accumulate. It is very frustrating at times.

For the most part OPTI will developing home-brand products to expand its portfolio, this drives more traffic and sales. R&D will be conducted more and more by partners, like the two initiatives for dairy in the USA.

OPTI will be launching new flavour flapjack, crisps, and hypertension OTC supplement and other cardiovascular alternatives.
Partner like OptiPharma, H&B, Alfasigma, etc will also contribute to new products .
Nutrillinea will also play its part, which will include a new scientific report around the study for the new BP OTC supplement.

OptiBiotix Health - Q&A podcast with CEO Stephen O'Hara

https://twitter.com/LEMMINGINVESTOR/status/1263444112969281541

Would you rather a placing of OPTI shares or risk losing a 10 x H&B agreement with OptiPharma? SBTX is a liquid asset that cost OPTI a total of £760k in cash and CLN. SBTX is still worth c£7m at 18p. OPTI cannot control the timing of a partner, thus capital injection and nor could OPTI have foreseen the pandemic that unfolded. We can all use hindsight but in reality, it is useless for future planning.

FWIW https://lemminginvestors.blogspot.com/2020/05/optibiotix-health-trading-update-for-3.html

https://lemminginvestors.blogspot.com/2020/05/skinbiotherapeutics-stuart-ashman.html